Defilade Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Defilade Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39M	Buy	+682,005	New	+$37.4M	5.22%	4

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Defilade Capital Management's BMRN Position: Q2 2026 in Review

Defilade Capital Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 682,005 shares worth $39M. The stake represents 5.22% of the portfolio and ranks #4 among its holdings.

561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Defilade Capital Management held 682,005 shares of BioMarin Pharmaceuticals worth $39M as of Q2 2026.
BioMarin Pharmaceuticals was a new Defilade Capital Management position in Q2 2026.
BioMarin Pharmaceuticals made up 5.22% of Defilade Capital Management's portfolio in Q2 2026, its #4 holding.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.